Rocket Pharma(RCKT.US)

Last Updated 19:00:00 ET
longbridge loading

Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks

Tip Ranks·
US
RCKT
-4.89%
US
PBE
+0.11%
US
BBH
+0.68%
Tip Ranks·
US
RCKT
-4.89%
US
PBE
+0.11%
US
BBH
+0.68%

Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results

Market Beat·
US
RCKT
-4.89%
US
PBE
+0.11%
US
BBH
+0.68%
Market Beat·
US
RCKT
-4.89%
US
PBE
+0.11%
US
BBH
+0.68%

Rocket Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
RCKT
-4.89%
Earnings Watch·
US
RCKT
-4.89%

RCKT Q1'26 Earnings: revenue estimate is 0 USD

TradingView·
US
RCKT
-4.89%
US
BBH
+0.68%
US
SBIO
-1.24%
TradingView·
US
RCKT
-4.89%
US
BBH
+0.68%
US
SBIO
-1.24%

<![CDATA[Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher]]>

Pharmexec·
US
RCKT
-4.89%
US
TEVA
+0.12%
Pharmexec·
US
RCKT
-4.89%
US
TEVA
+0.12%

<![CDATA[Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher ]]>

Pharmexec·
US
RCKT
-4.89%
US
LABU
-2.35%
US
XBI
-0.69%
Pharmexec·
US
RCKT
-4.89%
US
LABU
-2.35%
US
XBI
-0.69%

Rocket to sell PRV for $180m to advance gene therapy pipeline

Pharmaceutical Business Review·
US
RCKT
-4.89%
US
PBE
+0.11%
US
SBIO
-1.24%
Pharmaceutical Business Review·
US
RCKT
-4.89%
US
PBE
+0.11%
US
SBIO
-1.24%

Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway

Tip Ranks·
US
RCKT
-4.89%
US
IBBQ
+0.07%
US
FBT
+0.54%
Tip Ranks·
US
RCKT
-4.89%
US
IBBQ
+0.07%
US
FBT
+0.54%
© 2026 Longbridge｜Disclaimer